Competition and Markets Authority (CMA) levies fines of £2.3 million to three companies who conspired to inflate price of fludrocortisone

The CMA found Amilco and Tiofarma agreed to stay out of the market for fludrocortisone so that Aspen could maintain its position as sole supplier in the UK. Investigation has resulted in fines totalling ~ £2.3 million and a payment of £8 million directly to the NHS.

Source:

PharmaTimes